Juan Carlos Ramirez (CSO/CTO) and Natalia Elizalde (Business Development Director) attended this congress.
During these four days, VIVEbiotech organized different meetings with Applied Research Centers and Biotech Companies to discuss about LENTISOMA technology and its relevant safety related advantages as well as about its services as a GMP CDMO spezialiced in Lentiviral vectors.
It is very relevant to notice the great and progressive advance of the Gene Therapy field in the last years towards clinical development for different therapeutic indications.
This fact reinforces VIVEbiotech as a Company in the Lentiviral vector field.